Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease (Q24235834)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease	scientific article

Statements

scholarly article

0 references

0 references

1 reference

Europe PubMed Central

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease (English)

0 references

chronic renal insufficiency

1 reference

based on heuristic

inferred from title

object named as

Angharad Marks

5

0 references

author name string

Pawana Sharma

1

0 references

Rachel C Blackburn

2

0 references

Claire L Parke

3

0 references

Keith McCullough

4

0 references

Corri Black

6

0 references

publication date

5 October 2011

0 references

Cochrane Database of Systematic Reviews

0 references

Differing anti-proteinuric action of candesartan and losartan in chronic renal disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

21 January 2018

Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

21 January 2018

Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

21 January 2018

Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

21 January 2018

Effect of blood pressure control and antihypertensive drug regimen on quality of life: the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

21 January 2018

Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

21 January 2018

Long-term renoprotective effects of standard versus high doses of telmisartan in hypertensive nondiabetic nephropathies

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

21 January 2018

ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

21 January 2018

Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

21 January 2018

Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

21 January 2018

Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

21 January 2018

Effect of Lisinopril on the progression of renal insufficiency in mild proteinuric non-diabetic nephropathies

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

21 January 2018

Effects of combination treatment with losartan and trandolapril on office and ambulatory blood pressures in non-diabetic renal disease: a COOPERATE-ABP substudy.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

21 January 2018

Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

21 January 2018

Irbesartan effects on renal function in patients with renal impairment and hypertension: a drug-withdrawal study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

21 January 2018

Blood pressure response to conventional and low-dose enalapril in chronic renal failure

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

21 January 2018

Enalapril dosage in progressive chronic nephropathy: a randomised, controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

21 January 2018

Angiotensin receptor blockade and arterial compliance in chronic kidney disease: a pilot study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

21 January 2018

Comparison of the pharmacokinetics of fosinoprilat with enalaprilat and lisinopril in patients with congestive heart failure and chronic renal insufficiency

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

21 January 2018

Evaluation of the safety and efficacy of telmisartan and enalapril, with the potential addition of frusemide, in moderate-renal failure patients with mild-to-moderate hypertension

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

21 January 2018

Antihypertensive treatment with and without benazepril in patients with chronic renal insufficiency: a US economic evaluation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

21 January 2018

Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

21 January 2018

Efficacy and safety of benazepril for advanced chronic renal insufficiency

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

21 January 2018

Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

21 January 2018

Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

21 January 2018

Initial effect of enalapril on kidney function in patients with moderate to severe chronic nephropathy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

21 January 2018

Effect of enalapril on haemoglobin and serum erythropoietin in patients with chronic nephropathy.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

21 January 2018

Effect of enalapril on the progression of chronic renal failure. A randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

21 January 2018

Angiotensin converting enzyme inhibitors and progressive renal insufficiency. Current experience and future directions

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

21 January 2018

Metabolic effects of converting enzyme inhibitors: focus on the reduction of cholesterol and lipoprotein(a) by fosinopril

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

21 January 2018

Randomized controlled crossover study of the effect on proteinuria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with chronic renal disease and proteinuria

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

21 January 2018

Dual blockade of the renin-angiotensin system compared with a 50% increase in the dose of angiotensin-converting enzyme inhibitor: effects on proteinuria and blood pressure

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

21 January 2018

Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

21 January 2018

Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

21 January 2018

Racial differences in the renal response to blood pressure lowering during chronic angiotensin-converting enzyme inhibition: a prospective double-blind randomized comparison of fosinopril and lisinopril in older hypertensive patients with chronic re

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

21 January 2018

The effects of an ACE inhibitor and a calcium antagonist on the progression of renal disease: the Nephros Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

21 January 2018

Supratherapeutic doses of angiotensin receptor blockers to decrease proteinuria in patients with chronic kidney disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

21 January 2018

Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

21 January 2018

Chronic kidney disease, cardiovascular events, and the effects of perindopril-based blood pressure lowering: data from the PROGRESS study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

21 January 2018

Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

21 January 2018

Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

21 January 2018

Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

21 January 2018

Transforming growth factor beta1 and additional renoprotective effect of combination ACE inhibitor and angiotensin II receptor blocker in hypertensive subjects with minor renal abnormalities: a 24-week randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

21 January 2018

A five-year comparison of the renal protective effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with non-diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

21 January 2018

Valsartan in combination with lisinopril versus the respective high dose monotherapies in hypertensive patients with microalbuminuria: the VALERIA trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

21 January 2018

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (A

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

21 January 2018

Timing of nephrologist referral and arteriovenous access use: the CHOICE Study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

21 January 2018

Chronic kidney disease awareness, prevalence, and trends among U.S. adults, 1999 to 2000.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

21 January 2018

Effects of late referral to a nephrologist in patients with chronic renal failure

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

21 January 2018

A population-based study of the incidence and outcomes of diagnosed chronic kidney disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

21 January 2018

Screening strategies for chronic kidney disease in the general population: follow-up of cross sectional health survey

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

21 January 2018

Measuring inconsistency in meta-analyses

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

21 January 2018

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

21 January 2018

Prevalence of chronic kidney disease (CKD) in the Japanese general population predicted by the MDRD equation modified by a Japanese coefficient.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

21 January 2018

Unreferred chronic kidney disease: a longitudinal study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

21 January 2018

Economic burden of chronic kidney disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

21 January 2018

The timing of specialist evaluation in chronic kidney disease and mortality

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

21 January 2018

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

21 January 2018

The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

21 January 2018

Renin-angiotensin-aldosterone system and progression of renal disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

21 January 2018

Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT).

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

21 January 2018

Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

21 January 2018

Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

21 January 2018

Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

21 January 2018

A randomized, double-blind, parallel study on the safety and antihypertensive efficacy of losartan compared to captopril in patients with mild to moderate hypertension and impaired renal function

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

21 January 2018

Long-term effects of antihypertensive agents on proteinuria and renal function

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

OACE inhibition does not interfere with acute extrarenal or renal potassium disposal in chronic renal failure

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Renoprotective therapy: titration against urinary protein excretion

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: a systematic overview of randomized placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Angiotensin-converting enzyme inhibition in nondiabetic progressive renal insufficiency: a controlled double-blind trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

The influence of angiotensin-converting enzyme inhibition on renal tubular function in progressive chronic nephropathy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of ramipril on blood pressure and protein excretion rate in normotensive nondiabetic patients with proteinuria

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Vascular compliance is secured under angiotensin inhibition in non-diabetic chronic kidney diseases

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Long- versus short-term effects of two different ACE inhibitors on renal haemodynamics: preliminary results from an ongoing trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

ACE inhibitors captopril and enalapril induce regression of left ventricular hypertrophy in hypertensive patients with chronic renal failure

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment with the angiotensin II antagonist valsartan in patients with chronic renal failure and hypertension

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapeutic efficacy and tolerance of ramipril in hypertensive patients with renal failure.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of cilazapril in hypertensive patients with renal impairment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Angiotensin-converting enzyme inhibitors and kidney protection: the AIPRI trial. The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Tolerance and safety of enalapril

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Improving proteinuria, endothelial functions and asymmetric dimethylarginine levels in chronic kidney disease: ramipril versus valsartan

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and tolerability of losartan in hypertensive patients with renal impairment. Collaborative Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of valsartan on the progression of chronic renal insufficiency in patients with nondiabetic renal diseases

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Insulin Resistance, Inflammatory Biomarkers, and Adipokines in Patients with Chronic Kidney Disease: Effects of Angiotensin II Blockade

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Does stage-3 chronic kidney disease matter?: A systematic literature review.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Telmisartan in patients with mild/moderate hypertension and chronic kidney disease.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Improvement of lipid abnormalities associated with proteinuria using fosinopril, an angiotensin-converting enzyme inhibitor

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007751.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/14651858.CD007751.PUB2

0 references

PubMed publication ID

0 references

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q24235834&oldid=1613539092"